PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
94.20%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
94.81%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
98.22%
EPS growth of 98.22% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
98.22%
Diluted EPS growth of 98.22% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
200.00%
Share change of 200.00% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
200.00%
Diluted share change of 200.00% while CRVO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
12.59%
OCF growth of 12.59% while CRVO is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
12.59%
FCF growth of 12.59% while CRVO is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
66.67%
BV/share growth of 66.67% while CRVO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut SG&A while CRVO invests at 1275.64%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.